2010
DOI: 10.1016/j.healun.2010.05.035
|View full text |Cite
|
Sign up to set email alerts
|

Erythropoietin inhibits post-ischemic leukocyte adhesion but does not affect rejection in murine cardiac allografts

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
10
1
1

Year Published

2012
2012
2015
2015

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 6 publications
(12 citation statements)
references
References 43 publications
0
10
1
1
Order By: Relevance
“…The finding of platelet-endothelial cell interactions in postcapillary coronary venules suggests a novel mechanistic aspect in xenogeneic graft destruction, as it has been widely accepted that thromboembolic occlusion of the arteriolar bloodstream leads to infarction and tissue destruction. This is obviously different to allogeneic cardiac rejection, during which such platelet interactions were not observed [19] .…”
Section: Discussionmentioning
confidence: 84%
See 3 more Smart Citations
“…The finding of platelet-endothelial cell interactions in postcapillary coronary venules suggests a novel mechanistic aspect in xenogeneic graft destruction, as it has been widely accepted that thromboembolic occlusion of the arteriolar bloodstream leads to infarction and tissue destruction. This is obviously different to allogeneic cardiac rejection, during which such platelet interactions were not observed [19] .…”
Section: Discussionmentioning
confidence: 84%
“…The detection of reactive hyperaemia validates our experimental protocol for future IVM assessments of the xenografts' microcirculation addressing dynamic vasoreactivity changes during later reperfusion phases. In fact, prolonged reperfusion injury and the no-reflow phenomenon may hamper later adequate graft perfusion, as it has been observed in experimental cardiac allografts [19] .…”
Section: Discussionmentioning
confidence: 96%
See 2 more Smart Citations
“…We also postulate that erythropoietin (EPO) may provide a therapeutic benefit in ARDS due to its anti-inflammatory properties, its ability to positively modulate immune responses [18,19] and influence cell apoptosis [20,21,22]. Upregulation of anti-apoptotic genes, such as Janus tyrosine kinase-2, STAT5 (signal transducer and activator of transcription 5), Bcl-2, phosphatidylinositol 3, protein kinase B, mitogen-activated protein kinase and nuclear factor-κB (NFκB), after systemic EPO administration for 14 days has been described, and no immediate negative side effects were clinically observed [23].…”
Section: Introductionmentioning
confidence: 99%